Trial Name
|
GSK ID/NCT ID
|
Status
|
Design
|
DREAMM-1
|
117159/
NCT02064387
|
Active,
not recruiting
|
A Phase
I Open-label Study to Investigate the Safety, Pharmacokinetics,
Pharmacodynamics, Immunogenicity and Clinical Activity of
Belantamab Mafodotin (GSK285791) in Subjects with
Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic
Malignancies Expressing BCMA
|
DREAMM-2
|
205678/NCT03525678
|
Active,
not recruiting
|
A Study
to Investigate the Efficacy and Safety of Two Doses of Belantamab
Mafodotin (GSK2857916) in Subjects with Relapsed/Refractory
Multiple Myeloma Who are Refractory to a Proteasome Inhibitor and
an Immunomodulatory Agent and Have Failed Prior Treatment with an
Anti-CD38 Antibody
|
DREAMM-3
|
207495
|
Planned
|
A Phase
III Open-Label, Randomized Study to Evaluate the Efficacy and
Safety of Belantamab Mafodotin (GSK2857916) Compared to
Pomalidomide plus low-dose Dexamethasone (Pom/Dex) in Participants
with Relapsed/Refractory Multiple Myeloma
|
DREAMM-4
|
205207/NCT03848845
|
Recruiting
|
A Phase
I/II Single Arm Open-Label Study to Explore Safety and Clinical
Activity of Belantamab Mafodotin (GSK2857916) Administered in
Combination with Pembrolizumab in Subjects with Relapsed/Refractory
Multiple Myeloma
|
DREAMM-5
|
208887
|
Planned
|
A Phase
I/II, Randomized, Open-label Platform Study of Belantamab Mafodotin
(GSK2857916) with Innovative Combination Anti-Cancer Treatments in
Participants with Relapsed/Refractory Multiple Myeloma
|
DREAMM-6
|
207497/NCT03544281
|
Recruiting
|
A Phase
I/II Randomized Study to Evaluate Safety, Tolerability and Clinical
Activity of Belantamab Mafodotin (GSK2857916) Administered in
Combination with Lenalidomide plus Dexamethasone (Arm A), or in
Combination with Bortezomib plus Dexamethasone (Arm B) in Subjects
with Relapsed/Refractory Multiple Myeloma
|
DREAMM-7
|
207503
|
Planned
|
A Phase
III Study of Belantamab Mafodotin (GSK2857916) Administered in
Combination with Bortezomib plus Dexamethasone versus Daratumumab,
Bortezomib, and Dexamethasone in participants with
relapsed/refractory multiple myeloma
|
DREAMM-8
|
207499
|
Planned
|
A Phase
III, Multicentre, Open-Label, Randomized Study to Evaluate the
Efficacy and Safety of Belantamab Mafodotin (GSK2857916) in
Combination with Pomalidomide plus Low-Dose Dexamethasone (BPd)
versus Pomalidomide plus Bortezomib and Low-Dose Dexamethasone
(PVd) in Participants with Relapsed/Refractory Multiple
Myeloma
|
DREAMM-9
|
209664
|
Planned
|
A Phase
III Study of Belantamab Mafodotin (GSK2857916) Administered in
Combination with Bortezomib plus Lenalidomide and Low-Dose
Dexamethasone (VRd) vs. VRd in Participants with Newly
Diagnosed Multiple Myeloma who are Ineligible for
Transplant
|
DREAMM-10
|
207500
|
Planned
|
A Phase
III Study of Belantamab Mafodotin (GSK2857916) Administered in
Combination with a Novel Agent versus SoC
|
ISS / GSK
Co-Sponsored Study
|
209418
|
Recruiting
|
A Phase
I/II Dose-escalation and Dose-expansion Study of Belantamab
Mafodotin (GSK2857916)Administered in Combination with
Pomalidomide plus Low-dose Dexamethasone in Patients
with Relapsed/Refractory Multiple Myeloma Who Have
Received Two or More Prior Lines of Therapy That Must Have Included
Lenalidomide and a Proteasome
Inhibitor
|
GSK enquiries:
|
|
|
|
|
UK
Media enquiries:
|
Simon
Moore
|
+44 (0)
208 047 0907
|
(London)
|
|
|
|
|
|
|
US
Media enquiries:
|
Kristen
Neese
|
+1
(804) 217-8147
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
|
Danielle
Smith
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
Cautionary statements regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
Principal risks and uncertainties in the company's Annual Report on
Form 20-F for 2018.
Registered in England & Wales:
No. 3888792
|
|
|||
|
||||
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: August
23, 2019
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|